Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3211-3214

  Duranay, Murat ^a,c   Akay, Hatice ^a   Yilmaz, Fatma Meriç ^b   Şeneş, Mehmet ^b   Tekeli, Nurçin ^a   Yücel, Doǧan ^b  

^a Ministery of Health   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

CRP; Haemodialysis; Inflammation; L carnitine; Nutrition

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARNITINE; LIPID; PLASMA PROTEIN; SERUM ALBUMIN; TRANSFERRIN;

ADULT; ALBUMIN BLOOD LEVEL; AMYLOIDOSIS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MECHANISM; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INTERSTITIAL NEPHRITIS; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL;

BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CARNITINE; FEMALE; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; RENAL DIALYSIS; SERUM ALBUMIN; TRANSFERRIN;

EID: 33749987297     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl356     Document Type: Article

References (23)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: 16-23
2. Iseki K, Fuliyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000; 36: 820-825
3. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 2003; 41: 13-26
4. Yeun JY, Levine RA, Mantadilok V et al. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
5. Savica V, Santoro D, Mazzaglia G et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005; 15: 225-230
6. Dawson B, Trapp RG. Basic and Clinical Biostatistics, McGraw-Hill Companies, New York, USA: 2004; 69-70
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
8. Wan L, Hubbard RW. Determination of free and total carnitine with a random-access chemistry analyzer. Clin Chem 1998; 44: 810-816
9. Leschke M, Rumpf KW, Eisenhauer T et al. Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney Int 1983; 16: 143-146
10. Feinfeld DA, Kurian P, Cheng JT et al. Effect of oral L-carnitine on serum myoglobin in hemodialysis patients. Ren Fail 1996; 18: 91-96
11. Ahmad S, Robertson HT, Golper TA et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990; 38: 912-918
12. Golper TA, Goral S, Becker BN et al. L-carnitine treatment of anemia. Am J Kidney Dis 2003; 41: 27-34
13. Kletzmayr J, Mayer G, Legenstein E et al. Anemia and carnitine supplementation in hemodialysed patients. Kidney Int 1999; 69: 93-106
14. Caruso U, Leone L, Cravotto E et al. Effects of L-carnitine on anemia in aged hemodialysis patients with recombinant human erythropoietin: A pilot study. Dial Transplant 1998; 27: 499-506
15. Chazot C, Blanc C, Hurot JM et al. Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 2003; 59: 24-30
16. Kalantar-Zadek K, Kopple JD, Block G et al. A malnutrition - inflammation score is correlated with morbidity and mortality in maintainance hemodialysis patients. Am J Kidney Dis 2001; 37: A20
17. Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001; 15: 81-91
18. Panichi V, Migliori M, De Pietro S. Plasma C-reactive protein in haemodialysis patients. Blood Purif 1999; 17: 142-148
19. Bellinghieri G, Santoro D, Calvani M et al. Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients. J Ren Nutr 2005; 15: 13-17
20. Fellah H, Feki M, Hsairi M et al. Hyperhomocysteinemia and end-stage renal disease: Determinants and association with cardiovascular disease in Tunisian patients. Clin Chem Lab Med 2003; 41: 675-680
21. Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001; 15: 81-91
22. Yilmaz FM, Yilmaz G, Duranay M et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Sc J Clin Lab Invest 2005; 65: 739-745
23. Grazi G, Meriggioli M, Donati G. Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients? G Ital Nefrol 2004; 21: 204-207